List view / Grid view
The CHMP has adopted a positive opinion for Novartis’ Entresto…
25 September 2015 | By Victoria White
The CHMP has adopted a positive opinion for Novartis’ Entresto (sacubitril/valsartan), marking an important milestone towards the drug becoming available in the EU.
Novartis released new global guidelines for Investigator Initiated Trials...
8 July 2014 | By Novartis
Novartis released new global guidelines for Investigator Initiated Trials...
Novartis announced the signing of a licensing and commercialization agreement…
20 May 2014 | By Novartis
Novartis announced the signing of a licensing and commercialization agreement with Ophthotech Corporation for the exclusive rights to market Fovista® outside the United States...
Novartis has announced the launch of the Lucentis® (ranibizumab) pre-filled…
20 March 2014 | By Novartis
Novartis has announced the launch of the Lucentis® (ranibizumab) pre-filled syringe in Germany, with other markets to follow throughout 2014...
Novartis announced that the European Commission has approved the use…
6 March 2014 | By Novartis
Novartis announced that the European Commission has approved the use of Xolair® as an add-on therapy for the treatment of chronic spontaneous urticaria in adult and adolescent patients...
Novartis announced it will shortly submit a revised filing package,…
24 January 2014 | By Novartis
Novartis announced it will shortly submit a revised filing package, including new data analyses, for re-examination for conditional approval of RLX030 (serelaxin) for acute heart failure...
"Controlling relapses and preventing disability are key treatment goals for…
3 October 2013 | By Novartis
"Controlling relapses and preventing disability are key treatment goals for patients with MS..."
Data from head-to-head pivotal study showing secukinumab (AIN457) superiority to…
1 October 2013 | By Novartis
Data from head-to-head pivotal study showing secukinumab (AIN457) superiority to Enbrel®* (etanercept) in moderate-to-severe plaque psoriasis to be revealed...
New analysis of RELAX-AHF published in the European Heart Journal…
2 September 2013 | By Novartis
New analysis of RELAX-AHF published in the European Heart Journal and presented as a late breaker at the European Society of Cardiology congress[1],[2]...
Novartis announced that the EMA's CHMP has adopted a positive…
26 July 2013 | By Novartis
Novartis announced that the EMA's CHMP has adopted a positive opinion for approval of once-daily Ultibro® Breezhaler®...
RLX030 has the potential to address a serious unmet medical…
21 June 2013 | By Novartis
RLX030 has the potential to address a serious unmet medical need...
Novartis is joining the global multiple sclerosis community in celebration…
29 May 2013 | By Novartis
Novartis is joining the global multiple sclerosis community in celebration of World MS Day...
Latest global patient-use data...
26 March 2013 | By Novartis
Latest global patient-use data...
Novartis announced that the European Commission has approved llaris (canakinumab,…
1 March 2013 | By Novartis
Novartis announced that the European Commission has approved llaris (canakinumab, ACZ885)...
The FDA has approved Zortress®...
15 February 2013 | By Novartis
The FDA has approved Zortress®...
